Novel Regimens in COVID-19 Treatment

• Status: Recruiting
• Trial end date: 2030-12-01

Summary

Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.

• Phase: Phase 3

Details

• Lead Sponsor: Tanta University
• Treatments: Azithromycin; Chloroquine; Ivermectin; Nitazoxanide